TD Cowen analyst Daniel Brennan maintained a Buy rating on Guardant Health (GH – Research Report) today and set a price target of $60.00.
Daniel Brennan has given his Buy rating due to a combination of factors that highlight Guardant Health’s strong financial performance and future potential. The company posted a notable revenue beat in the first quarter, largely driven by increased clinical oncology volumes and pricing, alongside better-than-expected biopharma results. This performance led to a gross margin that exceeded consensus expectations, indicating operational efficiency.
Furthermore, management’s decision to raise the 2025 sales midpoint by $30 million, while maintaining margins and cash burn, suggests confidence in sustained growth. The company’s oncology business outperformed expectations with significant volume growth, particularly in the MRD segment, and the screening segment showed promising volume increases. These factors, combined with an increased price target to $60, underpin Brennan’s optimistic outlook for Guardant Health’s stock.
In another report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $60.00 price target.
Based on the recent corporate insider activity of 149 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GH in relation to earlier this year.